MaxCyte to Participate in Two Upcoming Investor Conferences
06 Novembre 2023 - 10:05PM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and
innovative bioprocessing applications, today announced Company
management will participate at two upcoming investor conferences.
- Stifel 2023 Healthcare
Conference Fireside Chat on Wednesday, November 15th at
9:10am ET
- Stephens Annual Investment
Conference Fireside Chat on Thursday, November 16th at
9:00am CT
A live and archived webcast of the event will be
available on the “Events” section of the MaxCyte investor relations
website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering
excellence to maximize the potential of cells to improve patients’
lives. We have spent more than 20 years honing our expertise by
building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today’s processes to
innovate tomorrow’s solutions. Our ExPERT™ platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on Twitter and LinkedIn.
MaxCyte Contacts:
US IR
Adviser Gilmartin
Group David Deuchler, CFA +1
415-937-5400 ir@maxcyte.com
US Media
Relations Spectrum Seismic
Collaborative Valerie Enes +1
408-497-8568 valerie@spectrumscience.com
Nominated Adviser and Joint Corporate
Broker Panmure
Gordon Emma Earl / Freddy Crossley Corporate
Broking Rupert Dearden +44 (0)20 7886 2500
UK IR
Adviser ICR Consilium
Strategic Communications Mary-Jane
Elliott Chris Welsh +44 (0)203 709
5700 maxcyte@consilium-comms.com
MaxCyte (NASDAQ:MXCT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
MaxCyte (NASDAQ:MXCT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024